Key result
Catheter-directed thrombolysis cuts 30-day mortality ~73% vs. systemic anticoagulation in submassive PE.
Why the study?
The optimal therapy for submassive pulmonary embolism remains in question, and data on the clinical efficacy of catheter-directed thrombolysis compared with systemic anticoagulation were limited.
Does catheter-directed thrombolysis plus systemic anticoagulation reduce all-cause mortality compared to systemic anticoagulation alone in patients with submassive pulmonary embolism?
Meta-Analysis (n=851)
Does catheter-directed thrombolysis plus systemic anticoagulation reduce all-cause mortality compared to systemic anticoagulation alone in patients with submassive pulmonary embolism?
This meta-analysis suggests catheter-directed thrombolysis reduces 30-day and 1-year all-cause mortality without significantly increasing major bleeding compared to systemic anticoagulation alone in submassive pulmonary embolism, though larger RCTs are needed to confirm these primarily observational findings.
Answers are grounded in this paper and cite their sources.
May support catheter-directed thrombolysis in submassive PE; leaves open confirmation by large RCTs.
BACKGROUND: The optimal therapy for submassive pulmonary embolism remains in question. The following meta-analysis compiles the current evidence comparing Catheter-Directed Thrombolysis (CDT) versus Systemic Anticoagulation (SA). METHODS: An electronic search through PubMed and Google scholar revealed studies comparing CDT versus SA in terms of mortality and major bleeding events. Thirty-day, 90-day, and one-year mortality results were analyzed. RESULTS: Six studies were included in the meta-analysis. Thirty-day and one-year mortality were less with CDT compared to SA (OR 0.27 [CI 0.11-0.67]; and OR 0.50 [CI 0.28-0.89]). Ninety-day mortality was similar between the two methods (OR 0.57 [CI 0.17-1.92]). Compilation of all studies reporting at least greater than 30-day mortality revealed less mortality with CDT (OR 0.51 [0.30-0.86]). Major bleeding was similar between the two treatments (OR 1.63 [CI 0.63-4.20]). CONCLUSION: CDT has less 30-day and 1-year mortality with equivalent rates of major bleeding compared to SA for treatment of submassive pulmonary embolism.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted a meta-analysis in Submassive (intermediate-risk) pulmonary embolism (n=851). Catheter-Directed Thrombolysis (CDT) plus systemic anticoagulation vs. Systemic Anticoagulation (SA) alone (i.e., heparin) was evaluated on 30-day all-cause mortality (OR 0.27, 95% CI 0.11-0.67). Catheter-directed thrombolysis reduced 30-day mortality and 1-year mortality compared to systemic anticoagulation in submassive PE.
Synapse has enriched 10 related papers. Consider them for comparative context: